Halozyme Therapeutics | HALO - Assets


Halozyme Therapeutics reported $2.58B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Baxter International USD 19.79B 55M Jun/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
DBV Technologies USD 223.2M 43.2M Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
MannKind USD 732.3M 12.1M Jun/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
United Therapeutics USD 7.22B 505.9M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025